Clinical Trial Update: SPM 927 (400mg/Day and 600mg/Day) as Adjunctive Therapy in Subjects With Partial Seizures With or Without Secondary Generalization [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating SPM 927 as adjunctive therapy for partial seizures (with or without secondary generalization) completed, sponsored by UCB Pharma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epilepsy
• Partial Seizures

Drugs mentioned

• SPM 927 (SPM 927)

Snippet

Sponsor: UCB Pharma | Conditions: Epilepsy | Phase 3 | Status: COMPLETED